Abstract A translational gap exists in Burkitt leukemia (B-AL) and Burkitt lymphoma (B-Ly) regarding miRNAs associated with clinicopathological features and outcome. The aim of this study was to evaluate differential miRNA expression in a single-center series of pediatric B-AL/B-Ly. Expression profiles of 800 miRNAs in 33 B-AL/B-Ly samples were evaluated using the NanoString nCounter System. Further validation was performed by qPCR utilizing miRNA-specific TaqMan assays. Significantly expressed miRNAs in B-AL/B-Ly were evaluated in silico to identify predicted targeted cancer-related pathways. Analysis of miRNAs deregulated in B-AL/B-Ly compared to normal control lymphoid tissue (NCLT) identified a consistent set of differentially expressed miRNAs, including miR-494-3p, miR-4286, and miR-19a-3p among the higher expressed miRNAs and miR-150-5p, miR-450b-5p, and miR-342-3p among the lower expressed miRNAs in B-AL/B-Ly compared to NCLT (FC > 1.5, p -adj 1.5, p -adj 1.5, p- adj < 0.05) was observed in the unfavorable outcome group. In summary, new miRNA signatures of relevance in B-AL and B-Ly could be recognized in this study. Studies in larger cohorts are required to further validate these findings.
Schneider et al. (Fri,) studied this question.